Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-14 23:05 | 2024-06-12 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $43.61 | 35,000 | $1,526,350 | 220,752 | -13.7% |
| 2024-05-21 23:07 | 2024-05-20 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.99 | 10,000 | $499,900 | 58,116 | -14.7% |
| 2024-05-17 23:05 | 2024-05-15 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $48.76 | 35,000 | $1,706,600 | 220,752 | -13.7% |
| 2024-04-19 23:05 | 2024-04-17 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $45.53 | 35,000 | $1,593,550 | 195,307 | -15.2% |
| 2024-03-29 23:05 | 2024-03-27 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $51.57 | 3,278 | $169,046 | 23,395 | -12.3% |
| 2024-03-15 23:07 | 2024-03-13 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $44.35 | 35,000 | $1,552,075 | 194,870 | -15.2% |
| 2024-03-13 23:05 | 2024-03-11 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | SALE | $44.71 | 7,874 | $352,047 | 949 | -89.2% |
| 2024-03-11 23:08 | 2024-03-07 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $45.00 | 1,634 | $73,530 | 1,400 | -53.9% |
| 2024-03-11 23:07 | 2024-03-08 | VCEL | Vericel Corp | Flynn Sean C. | Officer; SVP, General Counsel | Biological Products, (No Diagnostic Substances) | SALE | $45.33 | 8,115 | $367,853 | 167 | -98.0% |
| 2024-02-23 00:07 | 2024-02-20 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $50.01 | 722 | $36,107 | 23,395 | -3.0% |
| 2024-02-17 00:05 | 2024-02-14 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $47.92 | 35,000 | $1,677,200 | 174,008 | -16.7% |
| 2024-01-31 00:05 | 2024-01-29 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $44.22 | 2,300 | $101,706 | 23,395 | -9.0% |
| 2024-01-30 00:05 | 2024-01-25 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $44.02 | 200 | $8,804 | 25,695 | -0.8% |
| 2024-01-25 00:05 | 2024-01-22 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $41.85 | 8,000 | $334,775 | 25,895 | -23.6% |
| 2024-01-20 00:06 | 2024-01-17 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $38.28 | 33,452 | $1,280,375 | 169,985 | -16.4% |
| 2024-01-17 00:05 | 2024-01-12 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $38.09 | 2,200 | $83,798 | 30,895 | -6.6% |
| 2023-12-16 00:07 | 2023-12-13 | VCEL | Vericel Corp | Flynn Sean C. | Officer; SVP, General Counsel | Biological Products, (No Diagnostic Substances) | SALE | $34.42 | 1,538 | $52,944 | 4,467 | -25.6% |
| 2023-12-16 00:05 | 2023-12-13 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $35.58 | 24,000 | $853,800 | 169,985 | -12.4% |
| 2023-12-16 00:07 | 2023-12-14 | VCEL | Vericel Corp | Wotton Paul K | Director | Biological Products, (No Diagnostic Substances) | SALE | $37.31 | 5,000 | $186,550 | 26,802 | -15.7% |
| 2023-12-09 00:05 | 2023-12-06 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $34.14 | 24,397 | $832,909 | 176,742 | -12.1% |
| 2023-12-02 00:05 | 2023-11-30 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $35.41 | 17,447 | $617,798 | 827 | -95.5% |
| 2023-11-23 00:05 | 2023-11-20 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $36.40 | 5,000 | $182,000 | 53,007 | -8.6% |
| 2023-11-18 00:06 | 2023-11-15 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $37.70 | 662 | $24,954 | 1,305 | -33.7% |
| 2023-11-18 00:06 | 2023-11-15 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $38.02 | 300 | $11,406 | 33,095 | -0.9% |
| 2023-07-17 23:05 | 2023-07-14 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $38.84 | 1,000 | $38,840 | 33,395 | -2.9% |
| 2023-06-26 23:05 | 2023-06-22 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | Biological Products, (No Diagnostic Substances) | SALE | $36.00 | 3,000 | $108,000 | 34,395 | -8.0% |
| 2023-02-04 00:04 | 2023-02-02 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $31.00 | 330 | $10,230 | 675 | -32.8% |
| 2023-01-13 00:11 | 2023-01-10 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $27.13 | 39,938 | $1,083,598 | 157,066 | -20.3% |
| 2022-10-18 23:01 | 2022-10-14 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $25.47 | 331 | $8,431 | 875 | -27.4% |
| 2022-05-02 23:07 | 2022-04-29 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | SALE | $30.94 | 900 | $27,846 | 5,200 | -14.8% |
| 2022-03-04 00:06 | 2022-03-01 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $41.43 | 16,738 | $693,430 | 49,176 | -25.4% |
| 2021-12-23 02:54 | 2021-12-20 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.11 | 15,881 | $636,930 | 43,547 | -26.7% |
| 2021-12-02 00:07 | 2021-11-29 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $39.17 | 5,000 | $195,855 | 3,500 | -58.8% |
| 2021-10-28 23:09 | 2021-10-26 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $50.57 | 10,000 | $505,689 | 5,696 | -63.7% |
| 2021-10-28 23:12 | 2021-10-27 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $50.57 | 5,000 | $252,870 | 3,500 | -58.8% |
| 2021-10-01 23:12 | 2021-09-30 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $48.85 | 5,000 | $244,255 | 3,500 | -58.8% |
| 2021-08-31 23:10 | 2021-08-27 | VCEL | Vericel Corp | Flynn Sean C. | Officer; VP, General Counsel | Biological Products, (No Diagnostic Substances) | OPT+S | $55.11 | 7,200 | $396,760 | 2,419 | -74.9% |
| 2021-08-18 23:05 | 2021-08-16 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $48.03 | 15,000 | $720,480 | 5,623 | -72.7% |
| 2021-07-23 23:04 | 2021-07-21 | VCEL | Vericel Corp | Flynn Sean C. | Officer; VP, General Counsel | Biological Products, (No Diagnostic Substances) | OPT+S | $55.01 | 2,800 | $154,028 | 2,419 | -53.7% |
| 2021-07-16 23:07 | 2021-07-15 | VCEL | Vericel Corp | Flynn Sean C. | Officer; VP, General Counsel | Biological Products, (No Diagnostic Substances) | OPT+S | $51.18 | 10,000 | $511,786 | 2,419 | -80.5% |
| 2021-07-14 23:13 | 2021-07-12 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $53.54 | 20,000 | $1,070,876 | 5,623 | -78.1% |
| 2021-07-02 23:20 | 2021-06-30 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $57.14 | 134 | $7,657 | 39,319 | -0.3% |
| 2021-05-17 23:39 | 2021-05-14 | VCEL | Vericel Corp | Wotton Paul K | Director | Biological Products, (No Diagnostic Substances) | SALE | $50.52 | 5,000 | $252,611 | 26,602 | -15.8% |
| 2021-05-13 23:50 | 2021-05-11 | VCEL | Vericel Corp | Wotton Paul K | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $49.94 | 15,648 | $781,456 | 31,602 | -33.1% |
| 2021-04-20 23:15 | 2021-04-19 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $58.01 | 40,000 | $2,320,204 | 142,973 | -21.9% |
| 2021-03-31 23:17 | 2021-03-30 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $51.40 | 17,924 | $921,270 | 38,480 | -31.8% |
| 2021-03-30 23:50 | 2021-03-29 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $51.01 | 40,000 | $2,040,252 | 167,550 | -19.3% |
| 2021-03-03 00:15 | 2021-03-01 | VCEL | Vericel Corp | Colangelo Dominick | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $48.11 | 40,000 | $1,924,228 | 207,550 | -16.2% |
| 2020-12-24 00:10 | 2020-12-21 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $26.28 | 30,000 | $788,400 | 2,279 | -92.9% |
| 2020-12-24 00:11 | 2020-12-21 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $26.54 | 24,235 | $643,158 | 23,360 | -50.9% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.